New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections

Expert Rev Anti Infect Ther. 2024 Dec;22(12):1085-1098. doi: 10.1080/14787210.2024.2409408. Epub 2024 Sep 29.

Abstract

Introduction: The rising prevalence of difficult-to-treat, deep-seated invasive fungal diseases (IFD) has led to high mortality. Currently available antifungal treatments, administered predominantly orally or intravenously, may not sufficiently penetrate certain body sites, and/or are associated with systemic toxicity. Little is known about how to position alternative administration approaches such as inhalational and direct drug delivery routes.

Areas covered: This review provides an updated overview of unconventional drug delivery strategies for managing IFD, focusing on inhalational (to target the lungs) and direct delivery methods to the central nervous system, bone/joint, and eyes. Novel compounds (e.g. opelconazole) and existing antifungals with innovative drug delivery systems currently undergoing clinical trials and/or used off-label in the clinical setting are discussed.

Expert opinion: For both inhalational agents and direct delivery approaches, there are similar challenges that include the absence of: approved formulations for specific administration routes, delivery vehicles that are simple and safe to use whilst maintaining potency and efficiency of delivery, animal models suitable for investigating pharmacokinetic/pharmacodynamic profiles of inhaled antifungals, and consensus on the composite endpoints and intervals for of follow-up in clinical trials. To meet these challenges, cooperation of all stakeholders in drug development and regulation is required.

Keywords: Non-conventional; antifungal; delivery; direct; novel.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Animals
  • Antifungal Agents* / administration & dosage
  • Antifungal Agents* / pharmacokinetics
  • Drug Delivery Systems*
  • Humans
  • Invasive Fungal Infections* / drug therapy
  • Invasive Fungal Infections* / microbiology

Substances

  • Antifungal Agents